Payment overview · 2025
General Payments
$753.32
22 reported records · 15 companies
Healthcare provider profile · identity verified
Ali Salem, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · MONTCLAIR, CA · NPI 1376983122
Verified facts
What the public records show
CMS Open Payments records show Ali Salem, M.D. received $753.32 in general payments during 2025 across 22 reported records.
Itamar Medical Inc accounted for 18.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 16 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 69 claims for Jardiance by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 173 claims for Eliquis by this doctor in 2024.
SANOFI-AVENTIS U.S. LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LANTUS as an associated drug or biological on 12 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Lantus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Itamar Medical Inc | Unresolved — no canonical attribution shown | $138.43 | 18.4% | 1 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $103.22 | 13.7% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $101.38 | 13.5% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $99.43 | 13.2% | 4 | 2025 |
| Actelion Pharmaceuticals US, Inc. | Unresolved — no canonical attribution shown | $45.26 | 6.0% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $42.19 | 5.6% | 2 | 2025 |
| Regeneron Healthcare Solutions, Inc. | Unresolved — no canonical attribution shown | $33.04 | 4.4% | 1 | 2025 |
| Grifols USA, LLC | Unresolved — no canonical attribution shown | $32.11 | 4.3% | 2 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $30.93 | 4.1% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $28.78 | 3.8% | 1 | 2025 |
| UCB, Inc. | Unresolved — no canonical attribution shown | $27.99 | 3.7% | 1 | 2025 |
| United Therapeutics Corporation | Unresolved — no canonical attribution shown | $21.86 | 2.9% | 1 | 2025 |
| REVANCE THERAPEUTICS, INC. | Unresolved — no canonical attribution shown | $18.13 | 2.4% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $16.34 | 2.2% | 1 | 2025 |
| Resmed Corp | Unresolved — no canonical attribution shown | $14.23 | 1.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $753.32 | 22 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| WatchPATONE Normalized: watchpatone |
Device | Itamar Medical Inc | $138.43 | 1 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $103.22 | 2 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $101.38 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $99.43 | 4 | 2025 |
Source payment records
|
|||||
| UPTRAVI Normalized: uptravi |
Drug | Actelion Pharmaceuticals US, Inc. | $45.26 | 2 | 2025 |
Source payment records
|
|||||
| DUPIXENT Normalized: dupixent |
Biological | Regeneron Healthcare Solutions, Inc. | $33.04 | 1 | 2025 |
Source payment records
|
|||||
| Prolastin-C Liquid Normalized: prolastin c liquid |
Biological | Grifols USA, LLC | $32.11 | 2 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $30.93 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $28.78 | 1 | 2025 |
Source payment records
|
|||||
| Nayzilam Normalized: nayzilam |
Drug | UCB, Inc. | $27.99 | 1 | 2025 |
Source payment records
|
|||||
| OFEV Normalized: ofev |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $23.78 | 1 | 2025 |
Source payment records
|
|||||
| Tyvaso Normalized: tyvaso |
Drug | United Therapeutics Corporation | $21.86 | 1 | 2025 |
Source payment records
|
|||||
| JASCAYD Normalized: jascayd |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $18.41 | 1 | 2025 |
Source payment records
|
|||||
| DAXXIFY Normalized: daxxify |
Drug | REVANCE THERAPEUTICS, INC. | $18.13 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $16.34 | 1 | 2025 |
Source payment records
|
|||||
| AIRSENSE Normalized: airsense |
Device | Resmed Corp | $14.23 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 173 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
69 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
173 | 51 |
| SANOFI-AVENTIS U.S. LLC Exact reporting entity; no affiliate inference |
2025 | LANTUS open payments reported associated product |
CMS Open Payments — General Payments 12 supporting records · 11 recipient NPIs · example record 1233196856 |
Lantus · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 224 | 68 |
| Eliquis | Apixaban | 173 | 51 |
| Gabapentin | Gabapentin | 117 | 32 |
| Furosemide | Furosemide | 114 | 50 |
| Amlodipine Besylate | Amlodipine Besylate | 101 | 30 |
| Metoprolol Tartrate | Metoprolol Tartrate | 97 | 34 |
| Pantoprazole Sodium | Pantoprazole Sodium | 89 | 38 |
| Potassium Chloride | Potassium Chloride | 87 | 18 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 83 | 39 |
| Metformin Hcl | Metformin Hcl | 75 | 21 |
| Levetiracetam | Levetiracetam | 71 | 14 |
| Jardiance | Empagliflozin | 69 | suppressed |
| Losartan Potassium | Losartan Potassium | 69 | 24 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 54 | 19 |
| Baclofen | Baclofen | 54 | suppressed |
| Levothyroxine Sodium | Levothyroxine Sodium | 53 | 16 |
| Carvedilol | Carvedilol | 52 | 25 |
| Escitalopram Oxalate | Escitalopram Oxalate | 51 | 14 |
| Tramadol Hcl | Tramadol Hcl | 49 | 33 |
| Famotidine | Famotidine | 48 | 13 |
| Tamsulosin Hcl | Tamsulosin Hcl | 48 | 18 |
| Simvastatin | Simvastatin | 42 | suppressed |
| Januvia | Sitagliptin Phosphate | 41 | suppressed |
| Cephalexin | Cephalexin | 40 | 37 |
| Donepezil Hcl | Donepezil Hcl | 38 | 13 |
| Clopidogrel | Clopidogrel Bisulfate | 36 | 11 |
| Midodrine Hcl | Midodrine Hcl | 36 | 14 |
| Nifedipine Er | Nifedipine | 36 | 15 |
| Humulin R | Insulin Regular, Human | 35 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 35 | suppressed |
| Scopolamine | Scopolamine | 35 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 34 | suppressed |
| Omeprazole | Omeprazole | 33 | suppressed |
| Allopurinol | Allopurinol | 32 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 32 | 12 |
| Prednisone | Prednisone | 30 | 21 |
| Entresto | Sacubitril/Valsartan | 29 | suppressed |
| Lisinopril | Lisinopril | 29 | suppressed |
| Atrovent Hfa | Ipratropium Bromide | 28 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 28 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 27 | 22 |
| Lactulose | Lactulose | 27 | suppressed |
| Ozempic | Semaglutide | 27 | suppressed |
| Xarelto | Rivaroxaban | 27 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 26 | 12 |
| Quetiapine Fumarate | Quetiapine Fumarate | 25 | 12 |
| Sodium Chloride | 0.9 % Sodium Chloride | 25 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 24 | 15 |
| Azithromycin | Azithromycin | 24 | 19 |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 24 | suppressed |
| Meloxicam | Meloxicam | 24 | suppressed |
| Spironolactone | Spironolactone | 24 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 23 | suppressed |
| Lorazepam | Lorazepam | 22 | 13 |
| Alendronate Sodium | Alendronate Sodium | 21 | suppressed |
| Memantine Hcl | Memantine Hcl | 20 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 20 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 19 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 18 | suppressed |
| Amlodipine-Atorvastatin | Amlodipine/Atorvastatin | 17 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 17 | suppressed |
| Ketoconazole | Ketoconazole | 17 | suppressed |
| Metoprolol Succinate | Metoprolol Succinate | 17 | 13 |
| Santyl | Collagenase Clostridium Hist. | 17 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 16 | 14 |
| Ceftriaxone | Ceftriaxone Sodium | 16 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 16 | 16 |
| Duloxetine Hcl | Duloxetine Hcl | 16 | suppressed |
| Heparin Sodium | Heparin Sodium,porcine | 16 | suppressed |
| Primidone | Primidone | 16 | suppressed |
| Ranolazine Er | Ranolazine | 16 | suppressed |
| Digoxin | Digoxin | 15 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 15 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 15 | 11 |
| Finasteride | Finasteride | 14 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 14 | suppressed |
| Ibuprofen | Ibuprofen | 14 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Methenamine Mandelate | Methenamine Mandelate | 14 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 13 | suppressed |
| Colchicine | Colchicine | 13 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 13 | suppressed |
| Enoxaparin Sodium | Enoxaparin Sodium | 13 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 13 | suppressed |
| Latanoprost | Latanoprost | 13 | suppressed |
| Brilinta | Ticagrelor | 12 | suppressed |
| Cefdinir | Cefdinir | 12 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 12 | suppressed |
| Glipizide | Glipizide | 12 | suppressed |
| Glycopyrrolate | Glycopyrrolate | 12 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 12 | suppressed |
| Levofloxacin | Levofloxacin | 12 | 12 |
| Novolog Flexpen | Insulin Aspart | 12 | suppressed |
| Nystatin-Triamcinolone | Nystatin/Triamcinolone Acet | 12 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 12 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 12 | suppressed |
| Valproic Acid | Valproic Acid | 12 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 11 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 11 | suppressed |
| Mirtazapine | Mirtazapine | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $753.32 · 22 records | Itamar Medical Inc | AIRSENSE, DAXXIFY, DUPIXENT, Dexcom G6 Transmitter, ELIQUIS, INSPIRE, JASCAYD, KRYSTEXXA, Nayzilam, OFEV, Prolastin-C Liquid, TRELEGY ELLIPTA, TZIELD, Tyvaso, UPTRAVI, WatchPATONE | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Boehringer Ingelheim Pharmaceuticals, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error